Tuesday, June 2, 2026

SC-Hardie Trading Ltd. and Another Vs. Addisons Paint and Chemicals Ltd.

# Spartan Trade Mark Dispute: How a 25-Year Collaboration Became a Battle for Brand Ownership — Hardie Trading Ltd. v. Addisons Paint and Chemicals Ltd.

---

## Introduction

The case of *Hardie Trading Ltd. and Another v. Addisons Paint and Chemicals Ltd.*, decided by the Supreme Court of India on September 12, 2003, is a landmark judgment in the field of trade mark law that touches upon some of the most fundamental yet contested questions in intellectual property jurisprudence — what constitutes "use" of a trade mark, when can a registered trade mark be removed from the register for non-use, what are "special circumstances" that excuse such non-use, and critically, whether a former licensee or agent can claim ownership over a trade mark that was always the property of the original proprietor. The case has its roots in a collaboration that began in 1946 between an Australian company and an Indian manufacturer, lasted for over two decades, and then descended into a bitter legal battle spanning nearly three decades across multiple courts in India. The Supreme Court, in this judgment delivered by Justice Ruma Pal, decisively settled the law on each of these issues in favour of the original proprietor, Hardie, and firmly rejected Addisons' attempt to appropriate trade marks that had always belonged to Hardie. The case is a masterclass in trade mark law and serves as an important reminder that a licensee or agent who uses a trade mark on behalf of its principal cannot, by that mere use, claim proprietorship of the mark, however long the arrangement may have lasted.

---

## Factual and Procedural Background

The story of this dispute begins in 1926 and 1927, when a company called James Hardie and Company Private Ltd. — the predecessor in interest of the first appellant, referred to throughout as "Hardie" — obtained registration of trade marks consisting of the words "Spartan" and "Spartan Velox" and a device depicting the rear view of the upper body of a helmeted warrior carrying a shield and spear, referred to as the "Hardie device," in Australia and New Zealand in respect of paints, lacquers, and other surface coatings. These registrations have continued without interruption till today. As far back as 1940, Hardie also took steps to register the words "Spartan" and "Spartan Velax" in India. The words were entered in the Register of Trade Marks at Calcutta in Hardie's name, and the registration was valid for what was then undivided India and other South Asian countries.

On November 6, 1946, Hardie entered into a collaboration agreement with the respondent, Addisons Paint and Chemicals Ltd., referred to as "Addisons," for a period of 20 years. Under this agreement, Addisons was to be Hardie's "Chief Agent" in India and other named territories for selling surface coatings supplied by Hardie. The agreement also envisaged Addisons being the registered user of the trade marks during the period of the agreement and also the setting up of a factory by Addisons at Madras to manufacture the surface coatings according to Hardie's formulae. Addisons undertook that all formulae and technical information supplied to it by Hardie would be treated as strictly confidential. Pursuant to this collaboration agreement, between 1946 and 1949, Hardie's products were marketed in India through Addisons under Hardie's registered trade marks and device. By 1948, Addisons had set up its own factory at Chennai for manufacturing paints, lacquers, and other surface coatings with technical know-how supplied by Hardie, and the products were then sold by Addisons under Hardie's trade mark and device, for which Addisons paid Hardie royalty at agreed rates.

A formal registered user agreement between Hardie and Addisons was executed on July 11, 1963. This agreement contained strict quality supervision clauses and specifically provided that the trade marks shall not be used in conjunction with or in close juxtaposition to any other trade mark and shall at all times be so described as to clearly indicate that they are the trade marks of Hardie and are being used by Addisons only by way of permitted use. The registered user agreement also gave Addisons an option to acquire Hardie's rights in the trade marks for a consideration calculated on the basis of the royalties payable for three years. The registered user agreement was initially for a period of three years and was operative up to August 31, 1968.

In 1967, Hardie had agreed to assign its rights in the trade marks to Addisons for a sum payable in pound sterling. The Reserve Bank of India allegedly refused permission to Addisons to remit the amount. Whatever the reason, the consideration was not paid and the assignment did not go through. In anticipation of the assignment, the registered user agreement had been cancelled on August 31, 1968. However, since the consideration was not paid and the assignment fell through, Hardie requested Addisons to discontinue the use of Hardie's trade marks. After correspondence between the parties, Hardie allowed Addisons to continue using the trade marks and device till December 1971.

On November 3, 1971, Addisons applied for registration of a device consisting of a frontal view of a standing helmeted warrior holding a shield and spear — a different warrior device from Hardie's rear-view warrior. On November 11, 1971, Addisons informed Hardie that with effect from December 1, 1971, it would discontinue the use of Hardie's trade marks and had made arrangements to market its products under its own brand name. This was followed by several newspaper advertisements by Addisons publicly announcing that its products would no longer be sold under the old trade marks but under the brand name "Addisons" with the pictorial representation of the standing warrior. On December 6, 1971, Hardie itself applied for registration of the composite marks of "Spartan" and the Hardie device in respect of surface coatings, but this application was withdrawn on April 26, 1974.

In November 1976, Addisons obtained registration of its standing warrior device. In the same year, it filed three applications before the Registrar of Trade Marks at Mumbai for registration of Hardie's actual trade marks — the words "Spartan" and "Spartan Velox." These applications were rejected on the ground of identity and deceptive similarity with Hardie's already registered trade marks. Between 1972 and 1977, negotiations took place between Hardie and the second appellant, Hansa Paints and Chemicals, referred to as "Hansa," for appointing Hansa as the registered user of Hardie's trade marks in India. A registered user agreement was ultimately executed between Hardie and Hansa on March 31, 1977.

About two months after this, on May 30, 1977, Addisons applied in Calcutta for rectification of the Register of Trade Marks by seeking deletion of Hardie's registered trade marks under Section 46(1) of the Trade and Merchandise Marks Act, 1958, on the ground of non-use for a continuous period of five years or more. On November 18, 1977, Addisons filed two more applications for registration of Hardie's actual device — the rear-view warrior — along with three additional applications for registration of the word "Spartan" and "Spartan Velox" and the device in Class 2 and Class 3.

In November 1978, Hardie and Hansa filed two suits — Suit Nos. 835 and 836 of 1978 — in the Calcutta High Court, seeking an injunction restraining Addisons from dealing in paints and other surface coatings under Hardie's trade marks or device. Interlocutory applications were filed which were disposed of by a consent order on February 22, 1979. The consent order allowed Hardie and Hansa to continue to use Hardie's registered trade marks and device, and allowed Addisons to use its own standing warrior device, until the disposal of the suits. Importantly, Addisons also voluntarily undertook to the court that it would not use the mark "Spartan" or Hardie's device of the warrior-rear until the disposal of the suit. Those suits are still pending.

In December 1979, Addisons filed a civil suit in the Madras High Court against Hansa, seeking an injunction restraining Hansa from selling paints in containers identical or deceptively similar to Hardie's trade marks. The rectification application filed by Addisons before the Joint Registrar of Trade Marks at Calcutta was allowed by order dated September 12, 1985, resulting in Hardie's trade marks being expunged from the Register of Trade Marks. Both Hardie and Hansa appealed to the Calcutta High Court before a learned Single Judge. The appeal was dismissed on July 6, 1990, and on a further appeal the Division Bench confirmed the Single Judge's order on August 22, 1997. This decision of the Division Bench became the subject matter of SLP No. 206 of 1998 before the Supreme Court.

Separately, Addisons applied before the Madras Registrar for registration of Hardie's device in its own name. On June 19, 1989, the Assistant Registrar at Madras allowed Addisons' application for registration of Hardie's device. Appeals preferred before the Madras High Court were dismissed by a learned Single Judge and, before the Division Bench, there was a difference of opinion. The Third Judge sided with the minority and the majority decision against Hardie became the subject matter of Civil Appeals Nos. 5307 to 5311 of 1993. Further, on June 2, 1992, the Registrar at Madras allowed Addisons' applications for registration of the words "Spartan" and "Spartan Velox." This was challenged in Civil Appeal Nos. 5312 and 12A-E of 1993. When the Supreme Court granted leave in October 1993, it directed status quo to be maintained, and that status quo continued operative throughout.

---

## The Dispute

The dispute before the Supreme Court involved three sets of closely connected questions. The first was whether Hardie's trade marks — the words "Spartan" and "Spartan Velox" registered in India since 1946 — could be removed from the Register of Trade Marks on the ground of non-use for a continuous period of five years or more under Section 46(1)(b) of the Trade and Merchandise Marks Act, 1958. The second was whether Addisons was entitled to registration of Hardie's warrior device in its own name, given the history of the collaboration. The third was whether the Madras Registrar's grant of registration of the words "Spartan" and "Spartan Velox" in Addisons' name could be sustained once the question of Hardie's marks being on the Register was resolved. Running through all three questions were deeper issues — the meaning of "use" of a trade mark, the role of "special circumstances" as a defence against non-use, the significance of a licensee or agent using a trade mark on behalf of the proprietor, and the equitable considerations that arise when a former agent attempts to appropriate the principal's intellectual property.

---

## Reasoning and Analysis of the Judge

**On who qualifies as a "person aggrieved" under Section 46**, Justice Ruma Pal drew an important distinction that had been missed by the courts below. Sections 46, 56, and 69 of the Trade and Merchandise Marks Act, 1958 all use the phrase "person aggrieved," but the phrase carries a different meaning in each context. Under Section 56, which deals with situations where the initial registration was wrongly made — such as a wrong entry, an entry made without sufficient cause, or absence of an entry — the interest of the public in maintaining a pure register justifies a wider interpretation of "person aggrieved." For this broader purpose, the House of Lords in *In re Powell's Trade Mark*, (1894) 11 RPC 4, had held that anyone in the same trade as the registered proprietor whose legal rights might be limited by the existence of the registration would have locus standi. However, for an application under Section 46, which is based not on any public mischief arising from a wrongful entry but purely on subsequent non-use of a validly registered mark, a stricter test must apply. The applicant must show that in some practical, non-fanciful sense it might be damaged or injured if the trade mark is allowed to stand on the Register, and must show "something approaching a sufficient or proper reason" for seeking expungement. Mere antagonism toward the registered proprietor is not enough. Justice Ruma Pal found that the courts below had erred in applying the broader Powell's test to what was a Section 46 application, but did not decide the issue afresh since the appellants had pressed the case primarily on the second and third aspects of Section 46 — non-use and special circumstances.

**On the meaning of "use" of a trade mark under Section 46(1)(b)**, the central question was whether "use" necessarily required physical sale of goods bearing the trade mark, or whether it encompassed something broader. The Joint Registrar, the Single Judge, and the Division Bench of the Calcutta High Court had all proceeded on the basis that "use" meant use of the trade mark on goods in respect of which the trade mark was registered — that is, actual sale of goods bearing the mark. Since neither Hardie nor Hansa had sold any goods bearing the trade mark during the relevant period of April 30, 1972 to April 30, 1977, they concluded there was non-use.

Justice Ruma Pal disagreed. She examined Section 2(2)(b) of the Trade and Merchandise Marks Act, 1958, which defines "use in relation to goods" to mean use of the mark "upon, or in any physical or in any other relation whatsoever, to such goods." The words "any" and "whatsoever" qualifying "other relation" give the definition a significantly broader scope than mere physical use or sale. Referring to *Hermes Trade Mark*, (1972) RPC 425, Justice Ruma Pal noted that in an English case involving an identical statutory formulation, the court had held that "other relation" covered use of the mark in advertisements, invoices, orders, and so on, and that "use in the course of trade" was wide enough to embrace the steps necessary for the production of goods as well as the actual placing of them on the market. The court in *Hermes* had found that the insertion of advertisements and placing of orders for parts during the relevant period, even without actual sale, constituted sufficient use.

An even more recent example was *Bon Matin Trade Mark*, (1989) RPC 536, where a French manufacturer's trade mark registered in the United Kingdom in 1979 was sought to be removed in 1984 on the ground of five years' non-use. The only use prior to the application was the issue of price lists and promotional literature on two occasions, and the first sale of goods did not take place until three years after a distributor was eventually found. The English court held that the proprietor's genuine and sustained efforts to establish a market in the United Kingdom constituted sufficient use. Justice Ruma Pal found that the Indian statute's definition, with the additional words "any" and "whatsoever," gave an even wider meaning than its English counterpart, and concluded that the word "use" in Section 46(1) may encompass actions other than actual sale.

**On whether an intention to abandon is a necessary part of non-use**, Justice Ruma Pal held that the courts below had committed a fundamental error by conflating two distinct legal concepts. Non-use under Section 46(1)(b) is not simply a matter of counting five years of inactivity; it requires that the non-use reflects a lack of bona fide use, which necessarily involves an examination of the proprietor's intention. The intention to abandon the trade mark is a necessary component of the non-use that justifies removal. This was recognised as early as 1884 by Chitty J. in *Mouson & Co. v. Boehm*, 26 Ch.D. 398, where the owner of a trade mark for soap who had not actively sold the soap for several years was nevertheless held not to have abandoned the mark because he had retained the mark, had not broken the moulds used to make goods bearing the mark, and had continued sending price lists. Chitty J. held that there was no absolute non-use for any sufficient time, taken in connection with all the circumstances, to show an intention to abandon.

The same principle was affirmed by the United States Supreme Court in 1911 in *Baglin v. Cusenior Co.*, 221 US 580, where the court held that the loss of trade mark rights by abandonment requires a finding of intent to abandon, and that while intent may be inferred from facts, the facts must be adequate to support the finding. Justice Ruma Pal also cited *American Home Products Corporation v. Mac Laboratories Pvt. Ltd. and Another*, MANU/SC/0204/1985 : AIR 1986 SC 137, where the Supreme Court of India had held that both the intention of the proprietor not to use the trade mark at the time of registration and the actual non-use subsequent thereto had to be proved to justify removal under Section 46(1)(a). The court in that case had found that even though goods had not been sold during the alleged period of non-use, the proprietor's steps to enter into a collaboration agreement, obtain licences, and procure samples were sufficient to negate the allegation of non-use.

Justice Ruma Pal further clarified that the courts below had wrongly read Section 46(3) — which provides that an applicant cannot rely on non-use which is shown to be due to special circumstances in the trade — as if the only way to negate non-use was by proving special circumstances. She held that there is a clear distinction between the "intention to abandon" which forms part of the "no bona fide use" concept under Section 46(1), and the "intention to use" under Section 46(3) which is a separate defence inferred from special circumstances. The proprietor can defeat an application for rectification either by showing it had no intention to abandon the mark or, alternatively, by proving that special circumstances existed that excuse the non-use. Both are independent avenues of defence, not a single cumulative condition.

Applying these principles to the evidence on record, Justice Ruma Pal found that from as early as October 6, 1971, before the relevant period even began, Hardie and Hansa were in active negotiations for a registered user agreement under which Hansa would in effect do what Addisons had been doing. The correspondence showed several meetings, a draft registered user agreement prepared by February 6, 1973, and final approval by Hardie given by letter dated October 15, 1973. The delay in executing the agreement was caused by three hurdles — first, the need to give Addisons one month's notice to cease using the trade marks, which expired on December 1, 1971; second, a lack of communication between Hardie's attorneys and Hansa; and third, the refusal of the Reserve Bank of India in 1976 to approve payment of royalty in Australian dollars under Section 28 of the Foreign Exchange (Regulation) Act, 1973. On November 26, 1976, Hardie's attorneys advised that pursuing the royalty payment route would be futile and recommended revising the agreement. The original draft was revised and the registered user agreement was finally executed on March 31, 1977 — within the relevant five-year period. This evidence, which was not disbelieved by any of the courts below, clearly negated any intention on Hardie's part to abandon the trade marks. There was therefore no "absolute non-user" of the trade marks during the relevant period.

**On special circumstances**, quite apart from the absence of any intention to abandon, Justice Ruma Pal also found that the courts below had erred in rejecting Hardie's plea of special circumstances under Section 46(3). Hardie had placed on record the Import Trade Control Policy for April 1972 to March 1974 and April 1974 to March 1975, which showed that paints, distempers, varnishes, and lacquers could only be imported by actual users — that is, manufacturers or producers of paints and lacquers in India. Since Hardie had no factory in India, it could not import its goods into the country. Even actual users who did import paints for their own use were required to use the imported goods only for producing goods specified for export, thereby keeping the domestic market for domestic producers.

The Joint Registrar had rejected this defence on the ground that the non-use was due to considerations of Hardie's own business interests and not to circumstances affecting the trade in general. The Single Judge had held that the reasons were "economic, commercial and other factors which were applicable only to the appellants." The Division Bench focused on a paragraph in an affidavit by one Andrew Buttress of Hardie, where it was stated that even assuming there was no import restriction, it was not economically possible for Hardie to put more goods on the market immediately. The Division Bench found that economic viability or market conditions was outside the concept of special circumstances.

Justice Ruma Pal rejected all three findings. She relied on *Aktiebolaget Manus v. R.J. Fullwood and Bland, Ltd.*, (1949) 66 RPC 71, where the English court had held that prohibitive tariffs that were practically effective to keep out foreign-manufactured machines constituted special circumstances. This case was remarkably similar in its facts — a Swedish company's milking machines had been imported through an agent, the import stopped, the agent claimed the trade mark as its own, and the question was whether the non-use by the Swedish company was justified. The answer was yes, because special circumstances prevailed. Justice Ruma Pal also cited the observation of Chitty J. in *Mouson & Co. v. Boehm* that a man who has a trade mark may properly have regard to the state of the market and the demand for goods, and that it would be absurd to suppose he lost his trade mark by not putting more goods in the market when it was glutted. She further referred to *BALI Trade Mark (Rectification Ch.D.)*, (1966) RPC 387, where Justice Ungoed Thomas had held that what had to be considered was not merely the existence of an absolute prohibition to import but the existence of conditions making impracticable the ordinary usages of international trade, and that a trade mark must be understood and applied in a business sense. The House of Lords had subsequently affirmed this decision in *Berlei (U.K.) Ltd. v. Bali Brassiere Co., Inc.*, (1969) 2 All ER 812. This view had been accepted as good law in India by the Calcutta High Court in *A.J. Vulcan v. V.S. Palanichamy*, AIR 1969 Cal 43, and in *Express Bottlers Services Pvt. Ltd. v. Pepsi Inc. and Others*, MANU/WB/0158/1988.

Justice Ruma Pal held that economic impracticability amounts to special circumstances. The import trade control policy created conditions that were not peculiar to Hardie alone but were generally applicable to all foreign manufacturers of paints and lacquers. It was not Hardie's personal commercial choice that kept it from the market — the regulatory environment made it impossible as a practical business matter for Hardie to operate in India without first establishing a factory, which would have required an enormous investment.

**On the critical factual point about Addisons' use of the trade marks**, Justice Ruma Pal emphasised a point of the utmost legal significance. Between 1946 and 1971, Addisons had been using Hardie's trade marks and device, but it had done so first as Hardie's chief agent under the collaboration agreement and then as the registered user under the registered user agreement. Under Section 48(2) of the Trade and Merchandise Marks Act, 1958, the permitted use of a trade mark by a registered user is deemed to be use by the proprietor thereof, and is deemed not to be use by the registered user. This statutory fiction meant that for all purposes under Section 46, Addisons' use of the trade marks from 1946 to 1971 was legally treated as Hardie's use, not Addisons' use. Addisons had therefore never "used" the trade marks on its own account at any time. This was reinforced by the Supreme Court's own earlier decision in *Cycle Corporation of India Ltd. v. T.I. Raleigh Industries Pvt. Ltd.*, MANU/SC/0886/1996 : AIR 1996 SC 3295.

After 1971, Addisons had publicly disassociated itself from the marks through newspaper advertisements and had not attempted to use the trade marks or device in any manner. In fact, Addisons had itself admitted in the written statements filed in the infringement suits pending in Calcutta that it had not used the trade marks from 1963 to 1977. Moreover, under the consent order dated February 22, 1979 passed by the Calcutta High Court, Addisons had voluntarily undertaken that it would not use the mark "Spartan" or Hardie's warrior device until the disposal of the suit, and had reiterated this undertaking on April 30, 1982. The suit was still pending. There was therefore no use by Addisons of the marks on its own account either before or after 1971.

**On Addisons' claim to register Hardie's device in its own name**, Justice Ruma Pal found that the Madras High Court had committed several serious errors. The High Court had proceeded on the erroneous premise that once the objections of Hardie and Hansa were overruled, Addisons' application for registration would follow automatically. It had also held that Hansa's use of the device subsequent to the 1979 consent order was "by brute use in controversial circumstances" and could not be treated as bona fide use. Justice Ruma Pal found both these conclusions to be fundamentally wrong. First, an application for registration under Section 18 of the Act requires independent scrutiny. The applicant — here Addisons — had to affirmatively prove that it was the proprietor of the device and that it had used or had a bona fide intention to use the device. Merely defeating the opponent's objections does not entitle the applicant to registration. Second, Hansa's use of the device from September 1979 onwards was expressly sanctioned by the consent order, and it was perverse to describe a use authorised by a court order as "brute use in controversial circumstances." Third, there was no dispute that the device was invented by Hardie or its predecessor prior to 1926 and had been registered in Hardie's name in Australia and New Zealand continuously thereafter. Hardie had also sold products in India under the device between 1946 and 1949. The principle that the manufacturer who is the first to use a device as a trade mark can alone claim property over it as a trade mark was affirmed by reference to P. Narayanan's *Law of Trade Marks (Trade Marks Act 1999) and Passing Off*, 5th Edition, page 34.

Justice Ruma Pal agreed with the dissenting judgment of Swamidurai J. in the Madras High Court that Hardie had manufactured goods and was the first to market them under its registered trade mark and device in India, and that the consent order had been correctly construed. She further noted that had the Court upheld Addisons' claim even on other grounds, this would have been an appropriate case for the Registrar to exercise his discretion under Section 18 to reject Addisons' application — because Addisons had not only failed to adduce positive proof of any intention to use the device but had actually consciously and publicly abandoned it in 1971. When Addisons applied for registration of the device in December 1977, it had been seven years since that conscious abandonment and there was no evidence of any steps taken in between to use the device. Moreover, Hansa's continued use of the device from 1979 onwards for so many years had made the device distinctive of Hansa's products, and allowing registration in Addisons' name would deceive the public.

**On the registration of the words "Spartan" and "Spartan Velox" in Addisons' name by the Madras Registrar**, Justice Ruma Pal disposed of this set of appeals on a short but conclusive ground. Since the Supreme Court had held that Hardie's trade marks could not have been removed from the Register, and since those registrations continued in Hardie's name, the question of registering identical marks in Addisons' name simply could not arise. There was no plea of bona fide concurrent use under Section 12 of the Act, and the Madras Registrar's order of June 2, 1992 allowing Addisons' application was accordingly set aside.

---

## Final Decision of the Court

The Supreme Court allowed all the appeals. In SLP (C) No. 206 of 1998, the decisions impugned — the orders of the Joint Registrar of Trade Marks at Calcutta, the Single Judge, and the Division Bench of the Calcutta High Court — were set aside, and Hardie's trade marks were restored to the Register of Trade Marks. In Civil Appeal Nos. 5307-5311 of 1993, the decision of the Madras High Court allowing Addisons' application for registration of Hardie's device was set aside. In Civil Appeal Nos. 5312 and 12A-E of 1993, the order of the Registrar at Madras dated June 2, 1992 granting registration of "Spartan" and "Spartan Velox" in Addisons' name was set aside. The status quo order previously granted by the Supreme Court was dissolved as a consequence of the appellants' success. The first two sets of appeals were allowed with costs, and the last set was allowed without any order as to costs.

---

## Points of Law Settled in the Case

This judgment settled several points of trade mark law of lasting importance. The Court definitively held that the word "use" in Section 46(1)(b) of the Trade and Merchandise Marks Act, 1958, is not confined to actual physical sale of goods bearing the trade mark but encompasses use "in any other relation whatsoever" to such goods, including use in advertisements, promotional literature, orders for goods, price lists, and other steps taken in the course of trade toward placing goods on the market. The Court also settled that an intention to abandon the trade mark is a necessary component of the non-use that justifies removal under Section 46(1), and that this is a separate and independent element from the special circumstances defence under Section 46(3). A proprietor can resist removal either by proving absence of intent to abandon or by proving special circumstances, or both — the two defences are not hierarchical but alternative. The Court further settled that even economic impracticability — such as import restrictions making it commercially unfeasible for a foreign manufacturer to place goods on the Indian market — can constitute "special circumstances in the trade" within the meaning of Section 46(3), provided the circumstances are not peculiar to that manufacturer alone but are generally applicable to all foreign manufacturers in the same trade. Importantly, the judgment also reinforced the statutory fiction under Section 48(2) that the permitted use of a trade mark by a registered user is deemed to be use by the proprietor, and therefore a licensee or agent who uses a trade mark on behalf of its principal acquires no proprietary rights over the mark through such use. Finally, the Court made clear that an application for registration under Section 18 must be judged on its own independent merits and is not automatically granted merely because the opponent's objections are overruled.

---

*Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation.*

*Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi*

---

## Case Details

**Title:** Hardie Trading Ltd. and Another Vs. Addisons Paint and Chemicals Ltd.

**Date of Order:** September 12, 2003

**Case Number:** Civil Appeal Nos. 5307-11, 5312 and 12A-E/1993 and 7294 of 2003 (Arising out of SLP (C) No. 206/1998)

**Neutral Citation:** MANU/SC/0705/2003; AIR 2003 SC 3377; (2003) 11 SCC 92; 2003 (27) PTC 241 (SC)

**Name of Court:** Supreme Court of India

**Name of Hon'ble Judges:** Justice Ruma Pal and Justice B.N. Srikrishna

---

## Suggested SEO Titles for Legal Journal

1. Hardie Trading Ltd. v. Addisons Paint: Supreme Court on Non-Use of Trade Mark, Special Circumstances and Registered User — A Complete Legal Analysis
2. Can a Former Licensee Claim Ownership of a Trade Mark? The Supreme Court's Answer in Hardie Trading v. Addisons Paint 2003
3. What is "Use" of a Trade Mark under Section 46 of the Trade and Merchandise Marks Act? The Definitive Supreme Court Ruling in Hardie v. Addisons
4. Special Circumstances and Trade Mark Non-Use: How Import Restrictions Saved Hardie's Spartan Trade Mark in India — Supreme Court 2003
5. Spartan Trade Mark Dispute: The 57-Year Legal Battle Between Hardie Trading and Addisons Paint Explained — (2003) 11 SCC 92
6. Section 46 Trade Marks Act 1958 — Removal for Non-Use: Landmark Supreme Court Judgment in Hardie Trading v. Addisons Paint and Chemicals
7. Registered User Cannot Claim Trade Mark Ownership: Key Lessons from Hardie Trading Ltd. v. Addisons Paint and Chemicals Ltd. (2003)

---

## SEO Tags

Hardie Trading Ltd v Addisons Paint and Chemicals, 2003 11 SCC 92, AIR 2003 SC 3377, Supreme Court of India trade mark, Section 46 Trade and Merchandise Marks Act 1958, non-use of trade mark India, removal of trade mark register India, special circumstances trade mark non-use, registered user trade mark India, Section 48 Trade and Merchandise Marks Act, bona fide use trade mark India, Spartan trade mark India, Spartan Velox trade mark, collaboration agreement trade mark India, trade mark rectification India, import restriction special circumstances trade mark, abandonment of trade mark India, person aggrieved Section 46, Section 18 Trade and Merchandise Marks Act registration, Justice Ruma Pal Supreme Court, Hermes Trade Mark 1972 RPC, Bon Matin Trade Mark 1989 RPC, Aktiebolaget Manus RPC 1949, BALI Trade Mark 1966 RPC, Mouson v Boehm 1884, Berlei Bali Brassiere 1969, American Home Products v Mac Laboratories, Cycle Corporation India v TI Raleigh, trade mark owner vs licensee India, intellectual property rights India, trade mark proprietorship agent India, paints lacquers trade mark dispute India, Madras High Court trade mark, Calcutta High Court trade mark rectification, Foreign Exchange Regulation Act Section 28, AdvocateAjayAmitabhSuman, IPAdjutor

---

## Headnote

**Hardie Trading Ltd. and Another v. Addisons Paint and Chemicals Ltd.** — (2003) 11 SCC 92 : AIR 2003 SC 3377 : 2003 (27) PTC 241 (SC) : MANU/SC/0705/2003 — Supreme Court of India — Civil Appeal Nos. 5307-11, 5312 and 12A-E/1993 and 7294 of 2003 (arising out of SLP (C) No. 206 of 1998) — Decided September 12, 2003 — Before Justice Ruma Pal and Justice B.N. Srikrishna.

The trade marks "Spartan," "Spartan Velox," and the device of a helmeted rear-view warrior were owned by Hardie, registered in India since 1940, and used in India through Addisons as its chief agent and later registered user from 1946 to 1971. The collaboration ended in 1971 with Addisons publicly renouncing the marks. Hardie negotiated a fresh registered user agreement with Hansa, executed in March 1977. Addisons applied in May 1977 for rectification of the Register under Section 46(1)(b) of the Trade and Merchandise Marks Act, 1958, alleging five years' continuous non-use. The Joint Registrar allowed the application and the Calcutta High Court affirmed it. Addisons also obtained registration of Hardie's device in its own name from the Madras Assistant Registrar. The Supreme Court allowed Hardie's appeals, holding: (i) the word "use" in Section 46(1)(b) encompasses use in any relation to goods including advertisements, price lists, orders, and pre-marketing steps, and is not confined to actual sale of goods bearing the mark, as defined in Section 2(2)(b) which includes use "in any physical or in any other relation whatsoever" to the goods; (ii) an intention to abandon the trade mark is a necessary component of non-use for the purposes of Section 46(1), and is an independent element separate from the special circumstances defence under Section 46(3); (iii) Hardie's evidence of sustained negotiations with Hansa for a new registered user agreement from 1971 to 1977, culminating in the registered user agreement on March 31, 1977, clearly negated any intention to abandon; (iv) the Import Trade Control Policy for 1972-1975 which restricted the import of paints and lacquers to actual manufacturers or producers, and which Hardie — having no factory in India — could not satisfy, constituted special circumstances in the trade within Section 46(3), as economic impracticability amounts to special circumstances; (v) Addisons' use of the trade marks from 1946 to 1971 was, by virtue of the statutory fiction in Section 48(2), deemed to be Hardie's use and not Addisons' use, so Addisons never "used" the marks on its own account; (vi) Addisons had publicly disassociated itself from the marks in 1971 and had voluntarily undertaken before the Calcutta High Court in 1979 not to use the marks till disposal of the suits — showing conscious abandonment; (vii) Addisons' application for registration of Hardie's device under Section 18 could not succeed automatically upon overruling Hardie's objections; independent proof of proprietorship and bona fide use or intention to use was required, which was absent; and (viii) since Hardie's marks could not be removed from the Register, the grant of registration of identical marks to Addisons at Madras was unsustainable in the absence of any claim of bona fide concurrent use under Section 12. All appeals allowed. Hardie's trade marks restored. Addisons' registrations set aside.

Asian Patent Attorneys Association (Indian Group) Vs Registrar General, Delhi High Court

The Delhi High Court, in Asian Patent Attorneys Association (Indian Group) v. Registrar General, Delhi High Court, W.P.(C) 1950/2018, decided on 30 January 2026 by a Division Bench comprising Justice C. Hari Shankar and Justice Om Prakash Shukla, set aside an administrative order that prohibited the filing of execution petitions in the High Court where the decree amount was below ₹2 crore. The judgment was delivered by the High Court of Delhi at New Delhi. No neutral citation was mentioned in the judgment.

The dispute arose from an administrative order dated 17 November 2016 issued after the enhancement of the Delhi High Court’s pecuniary jurisdiction from ₹20 lakh to ₹2 crore, directing the Registry not to accept fresh execution petitions involving money decrees up to ₹2 crore. The petitioner challenged the legality of this restriction, contending that litigants could not be denied the right to file execution petitions before the Court.

The High Court held that neither the Delhi High Court (Amendment) Act, 2015 nor any other provision empowered the Registry to impose a blanket bar on the filing of such petitions. The Court emphasized that while the Registry may raise objections regarding jurisdiction, it cannot refuse to accept filings. Questions relating to maintainability and jurisdiction must be decided judicially by the Court and not administratively by the Registry.

Allowing the writ petition in part, the Court quashed the portion of the administrative order that directed the Registry not to accept execution petitions involving decrees below ₹2 crore. The Court clarified that jurisdictional objections could still be raised by the Registry, but the matter must ultimately be placed before the Court for adjudication.

[Disclaimer: Readers are advised not treat this as a substitute for legal advise as it may contain errors in perception,interpretation and presentation of facts and law.]

===

Delhi High Court Reaffirms Right of Litigants to Access Courts: Registry Cannot Refuse Filing of Execution Petitions Below ₹2 Crore

 Powers of Delhi High Court Registry and Right to Access Courts

Introduction:

The judgment delivered by the Delhi High Court on 30 January 2026 in Asian Patent Attorneys Association (Indian Group) v. Registrar General, Delhi High Court is an important decision concerning access to justice and the powers of court registries. The case arose from an administrative order issued by the Delhi High Court Registry after the enhancement of the Court's pecuniary jurisdiction from ₹20 lakh to ₹2 crore under the Delhi High Court (Amendment) Act, 2015.

The central issue before the Court was not whether execution petitions involving decrees below ₹2 crore should ultimately be heard by the High Court or District Courts. Rather, the question was whether the Registry could completely refuse to accept such petitions at the filing stage. The judgment is significant because it reinforces the principle that administrative authorities attached to courts cannot prevent litigants from approaching the judiciary and that questions of jurisdiction must ultimately be decided by judges exercising judicial power.

Factual and Procedural Background:

The petitioner, Asian Patent Attorneys Association (Indian Group), challenged an Administrative Order dated 17 November 2016 issued by the Registrar (Original) of the Delhi High Court. The order directed the Registry not to accept fresh execution petitions where money decrees were for amounts up to ₹2 crore. The order was based on the enhancement of the pecuniary jurisdiction of the Delhi High Court from ₹20 lakh to ₹2 crore through the Delhi High Court (Amendment) Act, 2015, which came into force on 26 October 2015.

The administrative order further directed identification and transfer of pending execution petitions involving decrees up to ₹2 crore to the concerned District Courts. Following the order, a note was also published in the cause list informing litigants that fresh execution petitions concerning decrees up to ₹2 crore would not be accepted by the High Court Registry.

Before the Division Bench, the petitioner confined its challenge only to the first part of the administrative order which prohibited acceptance of fresh execution petitions. The petitioner did not challenge the transfer of already pending matters to District Courts.

Dispute Before the Court:

The dispute concerned whether the Delhi High Court Registry could refuse to accept execution petitions merely because the decree amount was below ₹2 crore.

The petitioner argued that Section 37 of the Code of Civil Procedure, 1908 recognizes the continuing authority of the court that originally passed the decree. It was submitted that even after enhancement of pecuniary jurisdiction, execution petitions could remain maintainable before the High Court. At the very least, whether a petition was maintainable was a judicial question requiring adjudication by a court and not a matter that could be decided administratively by the Registry.

On the other hand, the respondent relied upon the Delhi High Court (Amendment) Act, 2015 and argued that the administrative order was intended to give effect to the legislative change that transferred jurisdiction over matters valued below ₹2 crore to District Courts.

The Court therefore had to determine whether the Registry could impose a blanket prohibition on filing such petitions and whether the administrative order had legal authority.

Reasoning and Analysis of the Court:

The Division Bench held that the impugned administrative order could not be sustained in law. The Court provided two principal reasons.

The first reason related to the scope of statutory authority. The Court observed that the administrative order purported to derive support from Section 4 of the Delhi High Court (Amendment) Act, 2015. However, the provision merely empowered transfer of pending proceedings from the High Court to District Courts. It did not authorize the Registry to create a threshold bar preventing fresh proceedings from being filed before the High Court.

According to the Court, a power to transfer pending proceedings cannot be interpreted as a power to prohibit institution of proceedings altogether. Consequently, the Registry exceeded the authority contemplated by the statute.

The second and more fundamental reason was based on the principle of access to justice. The Court emphasized that no litigant can ordinarily be prevented from filing a proceeding before a court. If the Registry believes that a matter is not maintainable or is beyond the jurisdiction of the court, it may raise an objection. However, the Registry cannot assume the role of a judicial authority and refuse registration of the matter.

The Court explained that where disagreement exists between the Registry and the litigant regarding jurisdiction, the matter must be placed before the Court for a judicial determination. Judicial power belongs to judges and not to administrative officers of the Registry.

The Bench drew a distinction between "filing" a proceeding and "entertaining" a proceeding. Filing merely allows a litigant access to the judicial process, whereas entertaining a matter involves a judicial decision regarding maintainability and jurisdiction. The Court held that the power to entertain or reject a matter rests exclusively with the court hearing the case.

In emphasizing this distinction, the Court relied upon the Supreme Court judgment in Lakshmi Rattan Engineering Works Ltd. v. Commissioner of Sales Tax, AIR 1968 SC 488. The Supreme Court had approved the view expressed in Kundan Lal v. Jagan Nath Sharma, AIR 1962 All 547, that the expression "entertain" does not mean filing or admission of an application but refers to the stage when the matter is actually considered by the court. By relying upon this principle, the Delhi High Court clarified that even if a question regarding jurisdiction exists, litigants cannot be denied the opportunity to place the matter before a judge.

The petitioner had also relied upon Gulab Chand Sharma v. Smt. Saraswati Devi, AIR 1975 Del 210 and the Supreme Court decision in Merla Ramanna v. Nallaparaju, AIR 1956 SC 87. These authorities were cited to argue that a court which originally passed a decree does not automatically lose jurisdiction to execute it merely because territorial or pecuniary jurisdiction subsequently changes.

The Bench acknowledged that these arguments deserved consideration. However, it consciously refrained from deciding whether execution petitions involving decrees below ₹2 crore would ultimately be maintainable before the High Court. The Court considered it more appropriate to leave that issue for determination by the judge hearing any particular execution petition on the judicial side.

This restraint reflects an important aspect of the judgment. The Court focused only on the legality of the administrative order and deliberately avoided issuing broad pronouncements regarding future jurisdictional disputes.

Final Decision of the Court:

The Delhi High Court partly allowed the writ petition. The Court set aside the portion of the Administrative Order dated 17 November 2016 which directed the Registry not to accept execution petitions where the decree amount was below ₹2 crore.

The Court clarified that the Registry remains free to raise objections concerning jurisdiction. However, if the litigant insists that the petition is maintainable, the Registry must place the matter before the Court for judicial consideration. No blanket administrative prohibition can prevent a litigant from filing such proceedings.

Point of Law Settled in the Case:

The most important legal principle emerging from this judgment is that a court registry cannot impose an administrative bar preventing litigants from filing proceedings. Questions relating to jurisdiction, maintainability, or competence of the court must be decided judicially and not administratively.

The judgment further clarifies that statutory provisions authorizing transfer of pending proceedings do not automatically empower administrative authorities to prohibit filing of fresh proceedings. The distinction between filing a matter and entertaining a matter remains fundamental. While a court may ultimately decline to entertain a proceeding for want of jurisdiction, a litigant cannot ordinarily be denied access to the judicial process at the threshold stage by an administrative order.

Case Title: Asian Patent Attorneys Association (Indian Group) Vs Registrar General, Delhi High Court

Date of Judgment: 30 January 2026

Case Number: W.P.(C) 1950/2018 

Neutral Citation: 2026:DHC:812-DB

Court: High Court of Delhi at New Delhi

Coram: Hon'ble Mr. Justice C. Hari Shankar and Hon'ble Mr. Justice Om Prakash Shukla

Disclaimer: Readers are advised not to treat this as substitute for legal advise as it may contain errors in perception, interpretation, and presentation.

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi


Headnote


The Delhi High Court held that the Registry cannot refuse to accept execution petitions merely because the decree amount is below ₹2 crore. Jurisdictional objections may be raised by the Registry, but the ultimate decision on maintainability must be taken by the Court exercising judicial power. Administrative directions cannot create a blanket bar on access to courts, and litigants must be permitted to place their cases before the court for adjudication.Suggested Google SEO Titles


Delhi High Court Rules Registry Cannot Refuse Filing of Execution Petitions Below ₹2 Crore

Access to Justice Prevails: Delhi High Court Strikes Down Registry Filing Ban

Asian Patent Attorneys Association v Registrar General Delhi High Court: Detailed Case Analysis

Can Court Registry Refuse Filing of a Case? Delhi High Court Answers

Delhi High Court on Powers of Registry and Right to Access Courts

Execution Petitions and Pecuniary Jurisdiction: Delhi High Court Clarifies Law

Important Delhi High Court Judgment on Filing of Execution Petitions

Registry vs Judicial Power: Delhi High Court Reaffirms Constitutional Access to Courts

Delhi High Court Judgment on Administrative Powers of Court Registry

Legal Analysis of Asian Patent Attorneys Association v Registrar General Delhi High Court


Suggested Google SEO Tags


Delhi High Court, Execution Petition, Pecuniary Jurisdiction, Court Registry Powers, Access to Justice, Delhi High Court Amendment Act 2015, Section 37 CPC, Code of Civil Procedure, Execution of Decrees, Judicial Review, Administrative Orders, Court Jurisdiction, Civil Procedure Law, Litigation Practice, Registry Objections, Maintainability of Proceedings,  High Court Original Side, Transfer of Cases, Jurisdictional Disputes, Legal News India, Case Analysis, Important Delhi High Court Judgments, Indian Civil Procedure, Execution Proceedings, Judicial Power, Court Administration, AdvocateAjayAmitabhSuman, IPAdjutor


SC-Cycle Corporation of India Ltd. Vs. T.I. Raleigh Industries Pvt. Ltd.

When Nationalisation Meets Trademark Law: The Supreme Court's Landmark Ruling in Cycle Corporation of India Ltd. vs. T.I. Raleigh Industries Pvt. Ltd.


Introduction

Few trademark disputes in Indian legal history arise from as remarkable a set of circumstances as the one decided by the Supreme Court of India on May 10, 1996, in Cycle Corporation of India Ltd. vs. T.I. Raleigh Industries Pvt. Ltd. and Others. This case sits at the crossroads of trademark law, industrial licensing law, and the consequences of government nationalisation of private industry — a unique confluence that makes it a deeply instructive precedent not only for intellectual property lawyers but for anyone seeking to understand how Indian courts balance commercial reality with statutory formality.

At the core of this case was a question that sounds almost paradoxical: can a company that manufactures goods and sells them in the market under a well-known brand name be considered a legitimate user of that brand, even if it never formally registered itself as a "registered user" under the applicable trademark statute? And when a foreign trademark owner tries to have its mark removed from the Indian register on the ground that no one has been using it for over five years, can an Indian company resist that attempt by pointing to its own long history of actual use — use that was unregistered, unrecognised by the registry, but undeniably real and continuous on the ground?

The Trade and Merchandise Marks Act, 1958, which was the governing legislation at the time, provided in Section 46(1)(b) that a registered trademark could be removed from the register if, for a continuous period of five years or more up to one month before the date of the removal application, the mark had not been used in good faith. Section 48 of the same Act created the concept of a "registered user" — someone other than the trademark proprietor who is formally registered to use the mark. Section 46(3) carved out an exception, protecting proprietors who could show that non-use was due to special circumstances in the trade, not any intention to abandon the mark.

The Supreme Court's navigation through these provisions, against the backdrop of a nationalised Indian bicycle industry and a decades-long collaboration with a British company, produced a judgment of lasting significance. The appeal was dismissed and the High Court's refusal to strike off the trademark from the register was upheld.


Factual and Procedural Background

The respondents, T.I. Raleigh Industries Pvt. Ltd. and others, were connected to the well-known British bicycle brand "Raleigh." Through their agents, they had registered the trademark "Raleigh" and 11 other trade marks — totalling 12 marks — under the Indian Merchandise Marks Act, 1889 (4 of 1889) and the Trade Marks Act, 1940 (5 of 1940). The Trade and Merchandise Marks Act, 1958 (43 of 1958), which came into force on October 3, 1958, repealed the predecessor Acts and is the statute under which this dispute was ultimately decided.

The chain of events that led to this case began as far back as November 3, 1948, when the respondents entered into an agreement with one Sudhir Kumar Sen to provide technical know-how to an Indian company that would be formed to manufacture bicycles and market them under Raleigh's Indian trade marks. Pursuant to this arrangement, a company called Sen Raleigh Ltd. was incorporated, which manufactured bicycles with technical assistance from the respondents and sold them under the Raleigh brand and trade marks belonging to the respondents. On April 24, 1954, Sen Raleigh was recorded as a permitted user of the trade marks. By a further agreement dated December 29, 1962, Sen Raleigh and the respondents agreed that Sen Raleigh would be a registered user of the marks for a further period extending up to 1976.

On September 8, 1975, Sen Raleigh Ltd. was taken over by the Government of India under the Industrial (Development and Regulation) Act, 1951 — commonly referred to as the IDR Act — and the Government assumed management of the company. The agreement dated December 29, 1962, was modified and the respondents were given the option to terminate it. A fresh agreement was then entered into on December 20, 1976, between the appellant, Cycle Corporation of India Ltd. — into which Sen Raleigh had by then been merged by operation of the IDR Act following nationalisation — and the respondent, under which the appellant used the 12 trade marks as a registered user for a period of 5 years.

On March 28, 1978, a joint application signed by the respondent as proprietor and by Sen Raleigh Ltd. as registered user was filed before the Registrar of Trade Marks. On October 24, 1980, Sen Raleigh was formally nationalised and vested in the appellant Corporation by publication of a notification under the IDR Act. On March 5, 1982, the respondent wrote to the appellant stating that in the absence of a new agreement, they were instructing their advocates to prevent the appellant from using the trade mark with effect from April 1, 1982.

On March 24, 1982, the appellant filed an application under Sections 32, 46, and 56 of the Trade and Merchandise Marks Act, 1958, before the High Court of Calcutta in Suit No. 266 of 1992, seeking to have the respondents' trade marks removed from the register. The appellant's case was, in essence, that neither the respondents nor any registered user had used the trade mark for a continuous period of five years or longer, and that further use by the respondents would be likely to deceive and cause confusion among the trade and public. Simultaneously, on March 25, 1982, the appellant also filed an application for registration of three trade marks in its own favour. However, by proceedings dated June 13, 1984, the Registrar of Trade Marks informed the appellant that the registered user applications were treated as abandoned because the appellant had failed to comply with statutory requirements.

The learned Single Judge of the Calcutta High Court dismissed the appellant's application by a judgment dated September 13, 1990. He held that the expression "by any registered proprietor" in Section 46(1)(b) extends beyond the registered proprietor and the registered user to include any bona fide or authorised user. He further held that special circumstances were available to the respondent as a defence for non-use even after 1979, since the supply of technical know-how by the respondent was not entirely absent after the termination of the collaboration agreement. He declined to rectify the trade marks and refused to strike them off the register. The Division Bench of the Calcutta High Court, in Appeal No. 13 of 1991, confirmed this decision by its judgment dated June 3, 1994. The Division Bench held that from October 25, 1980 onwards, the respondent had allowed and permitted the appellant to manufacture bicycles and pass off the goods under the respondents' trade marks. Though the collaboration and registered user agreements had stood expired from October 31, 1981, no new agreement was executed. There was no specific bar preventing an unregistered licensee from using a registered trade mark, so long as there existed a connection in the course of trade between the licensor and the licensee. The Division Bench also held that the non-registration of the user agreement by Sen Raleigh and the appellant was due to the default of the appellant, and that the appellant could not take a contradictory stand of applying for rectification while simultaneously seeking registration of its own marks. The appellant then came before the Supreme Court by way of special leave.


The Dispute

The dispute that came before the Supreme Court had three principal dimensions. The first was whether the appellant Corporation could be considered a "bona fide user" of the respondents' trade marks for the purpose of Section 46(1)(b), notwithstanding that it was not a formally registered user under Section 48(1) of the Act, particularly after the expiry of the registered user agreement on December 20, 1981, and the abandonment of the joint application. If the appellant was not a bona fide user, then the respondents too could not take credit for that use, and the five-year period of non-use might be established — which would then entitle the court to remove the mark.

The second dimension was whether the provisions of Section 46(3) — the special circumstances exception — were available to the respondents to defend themselves against the non-use allegation. The appellant argued that the respondents had not been using the marks as registered proprietors since April 20, 1954, and had failed to prove that they were prevented from using the marks for a period of five years or more preceding the date of the removal application due to special circumstances in the trade.

The third dimension was whether the High Court had properly exercised its discretion under Section 46 in refusing to rectify and strike off the trade marks from the register. The appellant contended that the public interest in having access to quality goods produced under the Raleigh brand should weigh in favour of keeping the marks alive in Indian hands, and that the court should have exercised its discretion to remove the marks.


Reasoning and Analysis of the Judge

The judgment of the Supreme Court was delivered by K. Ramaswamy, J., with whom Faizan Uddin, J., and G.B. Pattanaik, J., concurred.

On the Statutory Framework

The Court began by carefully setting out the relevant statutory provisions. Section 46(1)(b) of the Trade and Merchandise Marks Act, 1958, provides that a registered trade mark may be taken off the register if it is established that up to a date one month before the date of application, a continuous period of five years or longer had elapsed during which the trade mark was registered and during which there was no bona fide use thereof in relation to those goods by any proprietor for the time being. Section 46(3) provides that an applicant shall not be entitled to rely on non-use if the non-use was due to special circumstances in the trade and not to any intention to abandon or not use the trade mark.

Section 48 provides for registered users and states that the permitted use of a trade mark shall be deemed to be used by the proprietor thereof, and shall be deemed not to be used by a person other than the proprietor, for the purpose of Section 46 or for any other purpose for which such use is material under the Act or any other law.

The Court read these provisions together and explained their interplay clearly. The benefit of Section 46 — meaning the protection from having a mark struck off — would be available during the period for which an agreement was registered and use continued in furtherance of that agreement. Under Section 48(1), for the purpose of the deemed use fiction, the use must be either by the registered proprietor or by a formally registered user. An unregistered permitted person does not benefit from the deemed use fiction under sub-section (2) of Section 48. So far, the statutory position seemed to favour the appellant.

On the Concept of Bona Fide User and the Unregistered Licensee

However, the Court went further, and here lay the most important and original reasoning of the judgment. The Court held that even in the case of an unregistered licensee — that is, someone who is using the mark with the permission or consent of the proprietor but is not formally registered as a user — so long as there is an unbroken connection in the course of trade between the licensor and the passing off of the licensee's goods under the trade mark, there would be sufficient connection in the course of trade between the proprietor and the bona fide user of the trade mark by that unregistered licensee. This connection would link the registered proprietor and the user of the trade mark through the activities of the unregistered licensee. The permission or consent for such use may be express or may be implied by a long course of dealings. The appellant must, by course of conduct, be presumed to be a bona fide user for the purpose of Section 46(1)(b).

The Court acknowledged a decision of the Delhi High Court in K.R. Beri & Co. vs. Metal Goods Mfg. Co. (P) Ltd., reported at AIR 1980 Del 299, where the Division Bench had taken the view that an unregistered user of the trade mark, even with the consent of the proprietor, cannot be construed to be a registered user under Section 48(1), and that construing it otherwise would render sub-section (2) of Section 48 surplusage or otiose. The Supreme Court disagreed with this view, holding that it was not correct to hold that proving a bona fide user of an unregistered user when connection between the proprietor of the trade mark and the permitted user in relation to passing off of the goods under the trade mark are proved, renders sub-section (2) of Section 48 surplusage or otiose. The Delhi High Court's view on this specific point was, therefore, partly overruled.

The factual foundation for this conclusion was important. The High Court had found, and it was not disputed before the Supreme Court, that the appellant had entered into an agreement with Sen Raleigh — which was a permitted user of the trade marks — and had used the trade mark until November 1, 1976. Thereafter, by the registered user agreement dated December 20, 1976, the trade mark had been used for a period of 5 years. The Court found that it was not in dispute that till the date of filing of the application, the appellant had used the trade mark in passing off the bicycles under the trade mark of the respondent. The appellant had come to succeed to the position of Sen Raleigh by statutory operation following nationalisation under the IDR Act. This was therefore not a case of getting the trade mark registered under a predecessor Act and continuing under the Act for trafficking in the trade mark — an entirely different and less meritorious situation.

The Court also relied on American Home Products Corpn. vs. Mac Laboratories (P) Ltd., reported at (1986) 1 SCC 465, to reiterate that getting a trade mark registered without any intention to use it in relation to any goods but merely to sell it to others would be trafficking in the trade mark, and such conduct would not receive the assistance of the court. The court requires a real trade connection between the proprietor and the licensee of the goods, and the intention to use the trade mark must exist at the date of the application and must be genuine and bona fide and continue to subsist. In the present case, the facts showed that such a genuine trade connection existed throughout the relevant period.

On the Special Circumstances Exception under Section 46(3)

The Court held that while the burden lies on the registered proprietor to establish the special circumstances exception under Section 46(3), the application for rectification itself prima facie shows non-use for the relevant period, after which the burden shifts to the proprietor of the trade mark to affirmatively prove that the non-use was strictly due to special circumstances of the trade and not due to any intention not to use the mark. The non-use must be due to something that would have prevented use by the mark's owner independently of whether or not those special circumstances had arisen.

However, the Court concluded that it was not even necessary to enter into this question in the present case. The admitted position was that Sen Raleigh — admittedly a registered user — had been the channel through which the appellant had bona fide used the registered trade mark of the registered proprietor. Since Sen Raleigh was a registered user through whom the appellant had bona fide used the trade mark, there was no discontinuance or non-use of the trade mark by the respondent to establish the special circumstances argument. Sub-section (3) of Section 46 was therefore not attracted to the facts of the instant case at all.

The Court also chose not to decide whether the pendency of the application filed by the appellant under Section 48(1) for registration as a registered user would have constituted a special circumstance in favour of the respondent for the purpose of Section 46(3), leaving that question open.

On the Exercise of Discretion under Section 46

The Court affirmed that while exercising discretion under Section 46, the court must take into consideration not only the commercial interests of the parties but also the public interest. It referred to paragraph 21.82 at page 386 of the Law of Trade Marks and Passing-off by P. Narayanan (4th Edition), which states that ordinarily a mark will be expunged — taken off the register — when the factual circumstances necessary for its removal are established, unless it is shown that the case falls within the exceptions provided in sub-section (3).

The Court noted that the appellant had never at any point of time abandoned the use of the trade mark of the respondent-registered proprietor till the filing of the application. Although the appellant had not used the trade mark by itself since 1954 and after the expiry of the permitted use by Sen Raleigh, once the respondent issued notice directing the appellant not to use the mark, the appellant came to use the same in passing off bicycles manufactured by it under the trade mark of the respondent. The High Court had, therefore, rightly declined to rectify the trade mark under Section 46(1)(b) of the Act. The Supreme Court found no persuasive reason to take a different view from that of the High Court. The High Court had, in its opinion, properly exercised its discretion and refused to rectify and strike off the trade mark from the register of trade marks.


The Final Decision of the Court

The Supreme Court dismissed the appeal. It upheld the judgment of the Division Bench of the Calcutta High Court dated June 3, 1994, which in turn had confirmed the judgment of the Single Judge dated September 13, 1990. The respondents' 12 trade marks, including the mark "Raleigh," were not removed from the register. The appeal was dismissed without costs in view of the particular circumstances of the case.


Points of Law Settled in the Case

This judgment settled several important propositions under the Trade and Merchandise Marks Act, 1958, that continue to guide courts and practitioners in trademark matters.

The first and most important point is that the concept of a bona fide user under Section 46(1)(b) is not confined to formally registered users under Section 48(1). Even an unregistered licensee — someone using a trade mark with the express or implied permission of the registered proprietor — can constitute a bona fide user for the purposes of Section 46, provided there is an unbroken connection in the course of trade between the licensor and the passing off of the licensee's goods under the trade mark. This connection is what links the registered proprietor's ownership of the mark with the actual commercial use of the mark in the market.

The second point is a clarification of the relationship between Section 46 and Section 48. The deemed use fiction in sub-section (2) of Section 48 — which says that permitted use is deemed to be use by the proprietor — is specifically referable to the registered user or the permitted user who is registered. It does not extend automatically to unregistered permitted users. However, this does not mean that unregistered use is entirely irrelevant. The connecting link of passing off goods under the trade mark between the licensor and the unregistered licensee, when bona fide and with permission, can establish sufficient trade connection to prevent the mark from being taken off the register.

The third point relates to the burden of proof under Section 46(3). The burden to establish special circumstances for non-use lies on the registered proprietor of the trade mark. An application for rectification itself creates a prima facie presumption of non-use, following which the proprietor must affirmatively show that the non-use was due to special circumstances in the trade alone, not to any other cause and not to any intention to abandon the mark.

The fourth point is that Section 46(3) is not attracted when, on the facts, there has actually been bona fide use of the trade mark — whether by the registered proprietor, the registered user, or an unregistered licensee with a genuine trade connection. The special circumstances exception is only relevant when non-use is actually established.

The fifth point reinforces the principle from American Home Products Corpn. vs. Mac Laboratories (P) Ltd., (1986) 1 SCC 465, that trademark registration obtained merely to traffic in the mark — that is, to sell it rather than use it — will not receive judicial protection. There must be a real and genuine trade connection between the proprietor and the licensee, and the intention to use the mark must be genuine and subsisting.

The sixth point is that discretion under Section 46 must be exercised having regard to both commercial interest of the parties and broader public interest. When the factual circumstances for removal are not established — particularly because bona fide use by an authorised party has been proved — the court is entitled to decline to strike off the mark.


Case Details

Title: Cycle Corporation of India Ltd. Vs. T.I. Raleigh Industries Pvt. Ltd. and Others

Date of Order: May 10, 1996

Case Number: Civil Appeal No. 8266 of 1996 (arising from Judgment and Order dated June 3, 1994 of the Calcutta High Court in Appeal No. 13 of 1991)

Neutral Citation: (1996) 9 SCC 430; H-M/T/16307/S

Name of Court: Supreme Court of India

Name of Hon'ble Judges: K. Ramaswamy, J.; Faizan Uddin, J.; G.B. Pattanaik, J.


Disclaimer: Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi


Suggested SEO Titles

  1. Raleigh Bicycle Trademark Case: Supreme Court on Bona Fide Use by Unregistered Licensee in India
  2. Cycle Corporation of India vs. T.I. Raleigh Industries: Landmark Trademark Ruling Explained
  3. Trademark Non-Use and Nationalisation: The Supreme Court's Judgment in Cycle Corporation vs. Raleigh
  4. Section 46 Trade Marks Act 1958: When Can an Unregistered User Save a Trademark from Removal?
  5. Bona Fide User Under Indian Trademark Law: Lessons from Cycle Corporation of India Ltd. vs. T.I. Raleigh
  6. Trademark Rectification Refused: How the Raleigh Bicycle Case Shaped Indian IP Law
  7. Industrial Nationalisation and Trademark Rights: The Cycle Corporation vs. Raleigh Supreme Court Judgment
  8. Registered User vs. Bona Fide User in Indian Trademark Law: The Raleigh Bicycle Precedent

Suggested SEO Tags

Trademark Law India, Cycle Corporation vs Raleigh, bona fide user trademark India, Trade and Merchandise Marks Act 1958, Section 46 trademark removal India, Section 48 registered user India, trademark rectification India, trademark non-use India, unregistered licensee trademark India, trademark passing off India, nationalisation trademark India, IDR Act trademark, Raleigh bicycle trademark case, Supreme Court trademark 1996, trademark striking off register, special circumstances trademark non-use, trademark trafficking India, American Home Products vs Mac Laboratories, Indian trademark case law, intellectual property India, trademark registered user bona fide, trademark collaboration agreement India, AdvocateAjayAmitabhSuman, IPAdjutor


Headnote

The Supreme Court of India, in this appeal by special leave from the judgment of the Division Bench of the Calcutta High Court, held that the appellant — Cycle Corporation of India Ltd., a nationalised entity that had succeeded to the position of Sen Raleigh Ltd. by statutory operation under the Industrial (Development and Regulation) Act, 1951 — was a bona fide user of the respondents' trade marks for the purpose of Section 46(1)(b) of the Trade and Merchandise Marks Act, 1958, notwithstanding that it was not formally registered as a permitted user under Section 48(1) of the Act after the expiry of the registered user agreement dated December 20, 1976. The Court held that even an unregistered licensee, so long as there is an unbroken connection in the course of trade between the licensor-proprietor and the passing off of the licensee's goods under the trade mark, constitutes a bona fide user sufficient to prevent removal of the trade mark from the register under Section 46(1)(b). The deemed use fiction in sub-section (2) of Section 48 is referable to the registered user or the permitted user who is registered, and does not extend to unregistered permitted users; however, the connecting link of bona fide passing off of goods under the trade mark with the permission — express or implied — of the registered proprietor is independently sufficient to establish bona fide use under Section 46(1)(b). The Court further held that sub-section (3) of Section 46 — the special circumstances exception for non-use — was not attracted on the facts of this case, since bona fide use of the trade mark through the registered user Sen Raleigh and thereafter through the appellant had been established throughout the relevant period, leaving no non-use to be excused by special circumstances. On the question of discretion under Section 46, the Court held that the High Court had properly exercised its discretion in refusing to rectify and strike off the respondents' trade marks from the register of trade marks, since the factual circumstances necessary for removal had not been established. The view of the Delhi High Court in K.R. Beri & Co. vs. Metal Goods Mfg. Co. (P) Ltd., AIR 1980 Del 299, insofar as it held that bona fide use by an unregistered user with the proprietor's consent renders sub-section (2) of Section 48 surplusage, was partly overruled. Reliance placed on American Home Products Corpn. vs. Mac Laboratories (P) Ltd., (1986) 1 SCC 465, to reaffirm that there must be a real and genuine trade connection between the proprietor and the licensee at the date of the application for registration of the trade mark, and the intention to use the mark must be genuine, bona fide, and continuing. Appeal dismissed without costs.

Monday, June 1, 2026

Intas Pharmaceuticals Limited Vs. Sun Pharma Laboratories Limited

Delhi High Court Overturns Permanent Injunction Against Intas Pharmaceuticals; Holds BEVATAS Does Not Infringe Sun Pharma's BEVETEX Mark

Intas Pharmaceuticals Limited Vs. Sun Pharma Laboratories Limited RFA(OS)(COMM) 10/2026 | Decided on: 29 May 2026 | Delhi High Court | 2026:DHC:4879-DB: V Kameshvar Rao and Manmeet Pritam Singh Arora, H.J.

Sun Pharma Laboratories Limited, the registered proprietor of the trademark BEVETEX used for its anti-cancer drug containing the molecule Paclitaxel, instituted a suit in December 2017 alleging trademark infringement and passing off against Intas Pharmaceuticals Limited, which had launched an anti-cancer drug under the mark BEVATAS in 2016, containing the molecule Bevacizumab. The Trial Court and an Appellate Bench had both declined interim injunction, finding the marks structurally, phonetically and visually distinct. However, after a full trial, a learned Single Judge of the Delhi High Court decreed the suit in Sun Pharma's favour and permanently restrained Intas from using the mark BEVATAS, holding it deceptively similar to BEVETEX. Intas preferred the present appeal.

The Division Bench set aside the impugned judgment on multiple grounds. On the question of pleadings, the court found that Sun Pharma had filed a vexatious plaint by incorporating claims of passing off, misappropriation of goodwill and unfair competition despite being fully aware, prior to institution of the suit, that its drug and Intas's drug were not therapeutic substitutes and that no commercial loss had been suffered. During trial, Sun Pharma itself abandoned all monetary claims and pursued only a permanent injunction purportedly in public interest. The court held that such conduct amounted to an abuse of the process of law and the Trial Court ought to have rejected the plaint to that extent at the threshold.

On the infringement claim, the court held that the matter fell squarely under Section 29(2)(b) of the Trade Marks Act, 1999, requiring Sun Pharma to affirmatively establish likelihood of confusion on the part of the public. The court found that Sun Pharma had utterly failed to discharge this burden, having examined only a single witness , its own Sales Manager ,  who was neither competent nor credible to depose on the likelihood of confusion among the relevant class of public, being oncologists, trained nurses and pharmacists. No member of the relevant public was examined, and no documentary evidence of actual or likely confusion was produced despite nearly a decade of concurrent use of both marks in the market.

On the question of mark comparison, the court found that the prefixes BEV and BEVA are publici juris in the pharmaceutical industry, being derived from the International Non-Proprietary Name Bevacizumab, which is used by at least twenty manufacturers. Giving due emphasis to the distinctive suffixes ATAS and ETEX, and noting the difference in the fourth vowel sound — 'A' in BEVATAS and 'E' in BEVETEX — the court concluded that the marks, when assessed holistically and applying the anti-dissection rule, are neither phonetically, visually nor structurally similar. The court further noted that the two drugs are wholly dissimilar in composition, therapeutic indication, stage of treatment, dosage, mode of administration and price, and are admittedly not therapeutic substitutes. Given the highly specialised, prescription-only, hospital-administered nature of both drugs under oncologist supervision, the surrounding circumstances entirely negated any real possibility of confusion.

The court also found that the learned Single Judge had erred by deciding the infringement question solely on a prima facie visual comparison of the marks without undertaking any evidence-based assessment, effectively importing the statutory presumption under Section 29(3) of the Act which was plainly inapplicable. The Division Bench allowed the appeal, dismissed the underlying suit and awarded costs of the suit and the appeal in favour of Intas, directing the matter to proceed before the Taxation Officer.

[Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation and presentation of facts and law.]


BEVATAS vs BEVETEX: How Delhi High Court Overturned a Permanent Injunction Against Intas Pharmaceuticals in a Landmark Pharmaceutical Trademark Dispute

Post-Trial Trademark Infringement Standard in Pharmaceutical Cases

Introduction

The intersection of trademark law and public health has always been a sensitive and complex terrain for courts. When pharmaceutical companies fight over brand names, the stakes are not merely commercial lives can potentially be at risk if wrong drugs are dispensed to cancer patients. Yet, the law cannot be stretched beyond its limits on the mere invocation of public interest, especially when the party claiming to protect public interest has itself admitted it suffered no commercial loss and produced no credible evidence of any real confusion in the marketplace. The Delhi High Court's Division Bench judgment delivered on May 29, 2026 in Intas Pharmaceuticals Limited versus Sun Pharma Laboratories Limited is a landmark ruling that settles several important questions about how trademark infringement cases involving pharmaceutical products must be tried, what evidence must be led, and how courts must assess deceptive similarity between drug brand names at the post-trial stage. The court reversed a permanent injunction that had been granted against Intas Pharmaceuticals and, in doing so, laid down important principles that will guide pharmaceutical trademark litigation in India for years to come.

Factual and Procedural Background

Intas Pharmaceuticals Limited is a large multinational pharmaceutical company operating across multiple therapeutic segments including oncology. In 2016, Intas launched an anti-cancer drug under the brand name BEVATAS. This drug contains the molecule Bevacizumab, which is a monoclonal antibody  a biological drug used as a first line of treatment for several serious cancers including colorectal cancer, ovarian cancer, cervical cancer, lung cancer, metastatic breast cancer, and recurrent glioblastoma. The drug was approved by the Drug Controller General of India before its launch, went through rigorous clinical trials, and is administered intravenously only in hospital oncology settings by trained oncology nurses under the supervision of an Oncologist. By the time this appeal was heard, BEVATAS had become the market leader among drugs containing Bevacizumab in India, with approximately 22 percent market share, having been administered to over 75,000 cancer patients with about 12,000 patients currently undergoing treatment with the drug.

The name BEVATAS was coined by Intas by combining BEVA, taken from the first part of the molecule name Bevacizumab, and TAS, derived from the corporate name INTAS.

Sun Pharma Laboratories Limited is the registered proprietor of the trademark BEVETEX, which it applied for registration back in 1983, receiving the certificate of registration in 1990 under Class 5 of the Trade Marks Register. However, Sun Pharma admittedly did not actually use the mark BEVETEX for over three decades. It began commercially using BEVETEX only in 2015 for its own anti-cancer drug, which contains an entirely different molecule called Paclitaxel. Paclitaxel is a synthetic chemical cytotoxic agent, not a biological drug. It is used as a second line of treatment  that is, only after a patient's combination chemotherapy has failed, or after a relapse within six months of adjuvant chemotherapy  and only for metastatic breast cancer. Sun Pharma's drug BEVETEX is thus fundamentally different in composition, indication, mechanism of action, and stage of treatment from Intas's drug BEVATAS.

Within just about one year of Sun Pharma launching BEVETEX in 2015, Intas launched BEVATAS in October 2016. Sun Pharma learned about Intas's trademark application for BEVATAS in October 2016 and filed an opposition before the Trademark Registry on December 27, 2016. Claiming to have gained knowledge of the actual product only in October 2017, Sun Pharma instituted a suit before the Additional District Judge, South-East District, Saket Courts, Delhi, in December 2017, being CS (COMM) No. 39 of 2021, alleging trademark infringement, passing off, unfair competition, misappropriation of goodwill and reputation, and seeking permanent injunction, damages, rendition of accounts, and costs.

The Trial Court, vide a detailed order dated September 17, 2018, dismissed Sun Pharma's application for interim injunction, holding that the marks BEVATAS and BEVETEX were structurally, phonetically, and visually different and that no prima facie case of infringement or passing off was made out in view of the distinctions in the character, mode of administration, and other distinct factors of the two drugs. This order was upheld by an Appellate Bench of the Delhi High Court on January 9, 2020, and Sun Pharma's Special Leave Petition before the Supreme Court of India was dismissed on February 14, 2020.

After completion of evidence and trial, and after the valuation of the suit's reliefs was enhanced, the matter was transferred to the Original Side IP Division of the Delhi High Court. During the trial, Sun Pharma gave up its claim for damages, rendition of accounts, and all monetary reliefs, taking the stand that it was prosecuting the suit solely in public interest and had no commercial interest. Only the prayer for a permanent injunction restraining Intas from using the mark BEVATAS was pressed before the learned Single Judge.

The learned Single Judge, by the impugned judgment dated March 28, 2026, decreed the suit in favor of Sun Pharma and permanently restrained Intas from using the mark BEVATAS, holding it to be deceptively similar to BEVETEX and likely to cause confusion in the minds of consumers. Aggrieved by this order, Intas filed the present Regular First Appeal before the Division Bench under Section 96 of the Code of Civil Procedure, 1908.

The Dispute

The core dispute before the Division Bench was whether the learned Single Judge was justified in granting a permanent injunction against Intas on the ground that BEVATAS was deceptively similar to BEVETEX and likely to cause confusion among the public. Several sub-issues arose: whether Sun Pharma's plaint was properly framed and disclosed a legitimate cause of action; which specific provision of Section 29 of the Trade Marks Act, 1999 governed the dispute; whether the two drugs were similar or dissimilar goods; whether the two trademarks were visually, structurally, or phonetically similar; whether Sun Pharma had actually led any credible evidence to prove likelihood of confusion among the relevant class of public; and whether the learned Single Judge's approach of deciding infringement purely on a visual and phonetic comparison of marks at the post-trial stage was legally sustainable.

Reasoning and Analysis of the Court

On the vexatious nature of the plaint regarding passing off and unfair competition: 

The court noted that Sun Pharma's plaint was framed in the broadest possible manner, pleading multiple causes of action including trademark infringement, passing off, unfair competition, misappropriation of goodwill, and seeking monetary damages and rendition of accounts. Yet, soon after filing the suit, Sun Pharma represented before the Trial Court, in its rejoinder to the injunction application on January 29, 2018, that it had no commercial interest and was prosecuting the suit purely in public interest because Sun Pharma did not sell any medicine containing the molecule Bevacizumab. This stand was reiterated before the Appellate Court in FAO 447/2018, in the evidence affidavit of its sole witness PW-1 dated February 8, 2019, and again in cross-examination. The court held that this admission constituted a clear acknowledgment that Sun Pharma had suffered no commercial loss, no diversion of sales, and no damage to goodwill from Intas's use of BEVATAS. The court held that the dissimilarity of the two drugs' molecules was a fact known to Sun Pharma even before the suit was filed, yet it vexatiously pleaded passing off, misrepresentation, unfair competition, and monetary claims to create an illusion of a cause of action and a false sense of urgency. The court further observed that Sun Pharma ought to have restricted its suit from inception to the narrow claim of infringement based on alleged deceptive similarity, and that even at the stage of amendment of the plaint in August 2022 when the pecuniary valuation was enhanced, Sun Pharma did not delete the vexatious pleas it knew to be untenable. The court relied on ITC Ltd. v. Debts Recovery Appellate Tribunal, (1998) 2 SCC 70, and Bengal Waterproof Limited v. Bombay Waterproof Manufacturing Company and Anr., (1997) 1 SCC 99, to hold that proceeding to trial on such a plaint emboldened dishonest litigants and encouraged frivolous litigation, undermining the sanctity of the Statement of Truth under the Commercial Courts Act, 2015.

On the applicable sub-section of Section 29 of the Trade Marks Act, 1999: 

The court examined Sun Pharma's shifting legal positions. Before the Single Judge, Sun Pharma invoked Section 29(3) of the Act, which creates a statutory presumption of likelihood of confusion  but this presumption under Section 29(3) is only available when both the marks and the goods are identical, which falls under Section 29(2)(c). The court categorically held that the marks BEVATAS and BEVETEX are not identical, nor are the goods identical. Therefore, Section 29(2)(c) and the presumption of Section 29(3) were wholly inapplicable. The court also held that Section 29(4), which deals with dissimilar goods, was inapplicable since Sun Pharma had abandoned its plea of reputation. The court concluded that the dispute was squarely governed by Section 29(2)(b) of the Act  which applies where the defendant's mark is similar (not identical) to the registered mark and is used in relation to goods that are identical or similar to the goods covered by the registered mark  and that under this provision, the burden lay entirely on Sun Pharma to affirmatively prove likelihood of confusion among the public. The court was critical of Sun Pharma's vague and overbroad pleading of merely "Section 29" without specifying the sub-section, which the court described as inexact, intentional, and mischievous, enabling Sun Pharma to shift its legal arguments across different sub-sections at different stages.

On the evidentiary standard and Sun Pharma's failure to discharge the burden: 

The court emphasized that in a case where goods are not identical or closely similar, the likelihood of confusion cannot be presumed and must be proved by positive evidence. The court drew support from P. Narayanan's authoritative commentary on the Law of Trade Marks and Passing Off (Sixth Edition, 2004, paragraph 9.28), which states that where goods are not closely similar in character, evidence of witnesses is necessary to establish whether confusion is likely to occur. Sun Pharma itself had identified the relevant class of persons likely to be confused as being chemists, specifically pleading in paragraph 21(D) of the plaint that a chemist may give out the wrong drug on account of confusion or lack of stock. The court noted that Sun Pharma never even pleaded that an Oncologist might be confused at the prescription stage.

Despite identifying the chemist as the relevant class of public susceptible to confusion, Sun Pharma examined only a single witness, PW-1, who was its own Sales Manager. This witness parroted the plaint and made bald assertions about likelihood of confusion without any personal knowledge. In cross-examination, PW-1 admitted that the drug formulations of BEVATAS and BEVETEX were completely different, that the two drugs were a very different class of drugs with different indications and mode of action, that the toxicity profiles were different, and  most significantly  that there was no actual instance of confusion between the two marks on record. The only document PW-1 could point to as evidence of confusion was Ex. PW-1/9, an e-newspaper article about a 2011 incident of gross negligence by a pharmacist involving entirely different drugs  which PW-1 admitted had nothing to do with BEVATAS or BEVETEX and was merely a general example. The court held that PW-1 was not a competent witness to depose about likelihood of confusion as he belonged to a completely different class from chemists, Oncologists, and trained nurses. The court held PW-1's testimony to be unreliable and discarded it entirely. In contrast, Intas's witness DW-1 deposed that the drugs were administered under strict medical supervision in specialized oncological settings and that the possibility of confusion was negligible  testimony that remained largely uncontroverted in cross-examination.

On the learned Single Judge's approach: 

The court found that the impugned judgment dated March 28, 2026 determined the entire issue of infringement solely on a bare visual and phonetic comparison of the marks undertaken by the judge himself, without evaluating any of the evidence led at trial. The court noted that the learned Single Judge, while correctly setting out the governing legal principles in paragraphs 19 to 29 of the impugned judgment, proceeded directly to conclude at paragraph 28 that a likelihood of confusion existed, without adverting to any oral or documentary evidence of the parties. The court held that this approach, at the post-trial stage, was legally unsustainable. A bare comparison of marks by the court can at best constitute a prima facie view appropriate for deciding interim applications  it cannot form the basis of a final decree of permanent injunction after a full trial. The court noted that the impugned judgment effectively imported the statutory presumption under Section 29(3) of the Act without even acknowledging it, despite that presumption being wholly inapplicable on the facts of the case. The court also noted that after the interim injunction was denied and that denial was confirmed right up to the Supreme Court, the learned Single Judge would have needed clear and cogent evidence emerging at trial to form a contra view but Sun Pharma had produced no new documentary or oral evidence from any relevant member of the public after the dismissal of the interim injunction.

On the similarity of the two drugs: 

The court, relying on the undisputed comparative table of the two drugs set out in paragraph 9.9 of the impugned judgment itself, found that BEVATAS and BEVETEX were wholly dissimilar drugs. BEVATAS is a biological rDNA drug containing Bevacizumab, a monoclonal antibody, while BEVETEX is a synthetic chemical drug containing Paclitaxel. One is prescribed as the first line of treatment; the other only after failure of chemotherapy. Their indications are different, their dosage regimens are different, their infusion durations are different (90 minutes initially for BEVATAS versus 30 minutes for BEVETEX), their reconstitution procedures are different, and their side effect profiles are starkly different. The only overlap in indication is metastatic breast cancer (mBC), but even that overlap is not real because BEVATAS is given to mBC patients as a first line treatment while BEVETEX is given only when those patients have failed to respond to chemotherapy  meaning the same patient would never receive both drugs at the same time or in substitution for each other. Both parties had admitted that the two drugs were not therapeutic substitutes. The price difference  Rs. 25,990 for 100mg of BEVATAS versus Rs. 12,500 for 100mg of BEVETEX  was another factor militating against confusion. The court held that drugs that are not interchangeable, do not serve the same therapeutic purpose, and are not perceived by Oncologists, chemists, or patients as alternatives, are dissimilar for all purposes of trademark law. The court held that the mere fact that both drugs fall in the Nice Classification of medicinal and pharmaceutical preparations in Class 5 does not make them similar goods. The court relied on factors (c) and (d) of paragraph 35 of the Supreme Court's judgment in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73 (Cadila-2001), which require assessment of the nature, character, and performance of the goods.

On the phonetic and visual similarity of the trademarks: 

Applying the anti-dissection rule  meaning the marks must be compared as a whole  the court found that BEVATAS and BEVETEX were not phonetically or visually similar. The court observed that the prefix BEV and BEVA were publici juris in the pharmaceutical industry for drugs containing the molecule Bevacizumab. It was undisputed that at least seven other pharmaceutical companies Zydus (ZYBEV), Reliance Lifesciences (BEVACIREL), Hetero Drugs (CIZUMAB), Lupin (BEVAZZA), Emcure (BEVAREST), Abbott (BEVACIZAB), and Cadila Pharma (BEVARO)  marketed drugs containing Bevacizumab with trademarks using BEV or BEVA as prefix or suffix. Sun Pharma itself had no objection to any of these marks and acknowledged it claimed no exclusive right over BEV or BEVA. This meant that the distinctive portion of the marks to be compared were the suffixes: TAS in BEVATAS and ETEX in BEVETEX. The court noted that the molecule Bevacizumab is an International Non-Proprietary Name (INN) and is pronounced as beh-vuh-SIH-zoo-mab, and that given 20 pharmaceutical companies were making drugs with this molecule, Oncologists and chemists were well acquainted with the name. The fourth letter in BEVATAS is A (a vowel) and the fourth letter in BEVETEX is E (a vowel), and these vowels create distinctly different phonetic modulations — the word BEVATAS is likely pronounced as beh-vuh-tas while BEVETEX is pronounced as beh-veh-tex. The suffixes TAS and TEX are phonetically distinct and produce entirely different auditory impressions. The court also noted the suffix TAS was derived from Intas's corporate name and was used in approximately 40 other registered Intas trademarks such as LOMITAS, SPARTAS, CLARITAS, RUMENTAS, etc.  a fact that Oncologists and chemists were aware of. The court relied on the judgment in Astrazeneca UK Limited & Anr v. Orchid Chemicals & Pharmaceuticals Ltd., ILR (2007) I Delhi 874 (MERONEM/MEROMER), which held that due emphasis must be given to the uncommon letters in rival pharmaceutical marks once publici juris syllables are set aside. Considering the distinct suffixes ATAS versus ETEX, the court held the marks were not visually or structurally similar either, noting that the packaging of the two drugs was also completely different in colour scheme, font, layout, and overall visual presentation, with both products prominently displaying their respective active molecules  Bevacizumab and Paclitaxel  in large font on the packaging itself.

On the governing principles for infringement: 

The court synthesized the law from three landmark judgments. In Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73, the Supreme Court had identified seven factors for determining deceptive similarity of pharmaceutical marks  the nature of the marks, the degree of resemblance, the nature of the goods, the similarity in nature, character and performance of the goods, the class of purchasers and their education and degree of care, the mode of purchasing, and any other surrounding circumstances  emphasizing that weightage must be given to each factor depending on the facts of the case. In Kaviraj Pandit Durga Dutt Sharma v. Navaratna Pharmaceutical Laboratories, 1964 SCC OnLine SC 14, the Supreme Court held that in an infringement action, if the marks bear close similarity, no further evidence is required, but if they are merely similar (not an imitation), the plaintiff must establish that the mark used by the defendant so nearly resembles the plaintiff's registered mark as to be likely to deceive or cause confusion, and that deceptive similarity is essentially a question of fact. In Gufic Ltd. v. Clinique Laboratories, LLC & Anr., 2010 (43) PTC 788, a Coordinate Bench of the Delhi High Court had culled out that the test of deceptive similarity in infringement cases is the same as in passing off actions where marks are not identical, and five principles must be applied including overall structural and phonetic similarity and whether both marks convey the same idea. The court synthesized these authorities to hold that infringement adjudication in cases of similar (not identical) marks proceeds in two stages  a threshold comparison of marks by the court itself to assess degree of visual, structural, and phonetic resemblance, and if the marks are not found wholly dissimilar or nearly identical imitations, a second evidence-based stage where the court must assess deceptive similarity and likelihood of confusion on the basis of all the Cadila-2001 factors and the evidence led at trial.

On surrounding circumstances and public interest: 

Examining the surrounding circumstances in terms of the Cadila-2001 factors, the court found that since both drugs are Schedule H drugs requiring an Oncologist's prescription and administered only in oncology clinics by trained nurses under Oncologist supervision, there was little scope for casual or uninformed consumer choice at any stage  prescription, dispensing, or administration. The high price of both drugs (over Rs. 12,500 even for the smaller dose) meant purchasers would exercise heightened caution. The prominent display of the molecule name on the packaging ruled out confusion even for persons with imperfect recollection. The court also rejected Sun Pharma's belated oral submission before it that drugs could be sold over the counter without a prescription, noting this had not been pleaded and was not proved. On the question of public interest, the court found Sun Pharma's claim to be a red herring. The court held that Sun Pharma had no valid cause of action at all — it suffered no loss of revenue, no damage to goodwill, and its mark's distinctiveness was not eroded in any demonstrable way. The court concluded that Sun Pharma pursued the litigation to protect its purely commercial interest in the mark BEVETEX under the guise of public interest. The court also noted that after nearly ten years of concurrent use of both marks from 2016 to 2026, not a single instance of actual confusion in the market had been reported or proved.

On the case law cited by Sun Pharma: 

The court carefully distinguished each precedent cited by Sun Pharma. United Biotech Pvt. Ltd. v. Orchid Chemicals & Pharmaceuticals Ltd., 2012 SCC OnLine Del 2942 (FORZID/ORZID), was a rectification proceeding involving the same drug molecule Ceftazidime where the risk arose from direct substitutability of identical therapeutic agents with differing dosages  entirely unlike the present case. Sun Pharma Laboratories Limited v. BDR Pharmaceuticals International Pvt. Ltd. & Anr., 2020 SCC OnLine Del 623 (LABEBET/LULIBET), was a final judgment where parties elected not to lead oral evidence, and the drugs could be self-administered  again, an entirely different scenario. Novartis AG v. Crest Pharma Pvt. Ltd. and Anr., 2009 SCC OnLine Del 4390 (SECEF/CECEF), was an interim injunction order. Nutrica Pusti Healthcare Pvt. Ltd. v. Morepen Laboratories Ltd., 2021 SCC OnLine Del 263, was also an interim order. Glenmark Pharmaceuticals Ltd. v. Sun Pharma Laboratories Ltd., 2024 SCC OnLine Del 2707 (ISTAMET/INDAMET), also relied upon by Sun Pharma, was a prima facie finding by a Division Bench in an interim matter, and importantly involved self-administered diabetes drugs where patients themselves managed the medication  starkly different from hospital-administered oncology drugs. The court also referred with approval to the Division Bench judgments in Sun Pharmaceuticals Laboratories Ltd. v. Hetero Healthcare Ltd. and Another, 2022 SCC OnLine Del 2580 (LETROZ/LETERO), Sun Pharmaceuticals Industries Ltd. v. Anglo French Drugs & Industries Ltd. & Anr., 2014 SCC OnLine Del 4716 (OXETOL/EXITOL), Schering Corporation & Ors v. Alkem Laboratories Ltd., 2009 SCC OnLine Del 3886 (TEMODAL/TEMODAR vs TEMOKEM/TEMOGET), and Astrazeneca UK Limited & Anr v. Orchid Chemicals & Pharmaceuticals Ltd., ILR (2007) I Delhi 874 (MERONEM/MEROMER), all of which had held that despite phonetic similarities, no likelihood of confusion was found given the specialized nature of the drugs, therapeutic use, and modes of administration. The court noted that the judgment in Modi-Mundipharma Pvt. Limited v. Specialty Meditech Pvt. Ltd & Anr., 2025:DHC:5039-DB, supported the principle that where marks are an imitation and goods are identical, no further evidence is needed  but that this principle had no application where, as here, the marks were not an imitation and the goods were dissimilar.

Final Decision of the Court

The Division Bench allowed the appeal and set aside the impugned judgment dated March 28, 2026. The permanent injunction granted against Intas Pharmaceuticals was vacated. The suit filed by Sun Pharma was dismissed. The court found in favor of Intas on Issues 3, 4, 9, and 10 (relating to infringement, likelihood of confusion, proprietorship of BEVATAS, and honest adoption), and set aside the findings of the Single Judge on Issues 7 and 8 as well. The court awarded costs of the suit and the appeal in favor of Intas against Sun Pharma, directing Intas to file its bill of costs within 30 days, with the matter of quantum referred to the Taxation Officer to assess actual costs, payable by Sun Pharma within eight weeks of determination. Representatives of Intas were directed to appear before the Taxation Officer on July 13, 2026.

Points of Law Settled in the Case

This judgment establishes a number of important legal principles. At the post-trial stage in a trademark infringement suit under Section 29(2)(b) of the Trade Marks Act, 1999, where the marks are similar but not identical and the goods are similar but not identical, the court cannot grant a permanent injunction based solely on its own visual and phonetic comparison of the marks — an evidence-based assessment of likelihood of confusion among the relevant class of public is mandatory. The statutory presumption of likelihood of confusion under Section 29(3) is available only when both the marks and the goods are identical under Section 29(2)(c); it cannot be imported into cases falling under Section 29(2)(b). The mere fact that two drugs fall in the same Nice Classification — Class 5, medicinal and pharmaceutical preparations — does not make them similar goods for the purposes of trademark infringement if they are not interchangeable, do not serve the same therapeutic purpose, and are not perceived by the relevant class of professionals as alternatives. Where the plaintiff in a pharmaceutical trademark suit has identified a specific class of persons (such as chemists) as being susceptible to confusion, it must examine witnesses from that class; testimony by the plaintiff's own sales representative is not a substitute. The prefix BEV/BEVA is publici juris in the pharmaceutical trade for drugs containing the molecule Bevacizumab, and the court must give primacy to the distinctive, uncommon parts of rival marks when making a comparison. The deliberate filing of a vexatiously overbroad plaint incorporating causes of action the plaintiff knows to be untenable — such as passing off and misappropriation of goodwill when the plaintiff itself admits no commercial loss — is an abuse of process, and courts should not permit such plaints to proceed to trial. Trademark infringement litigation driven by commercial interest in protecting a mark cannot be dressed up as public interest litigation merely by abandoning monetary claims.

Case Title: Intas Pharmaceuticals Limited Vs. Sun Pharma Laboratories Limited

Date of Order: May 29, 2026

Case Number: RFA(OS)(COMM) 10/2026 

Neutral Citation: 2026:DHC:4879-DB

Name of Court: High Court of Delhi at New Delhi (Original Side, Division Bench)

Names of Hon'ble Judges: Hon'ble Mr. Justice V. Kameswar Rao and Hon'ble Ms. Justice Manmeet Pritam Singh Arora 

Disclaimer: Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

Suggested SEO Titles

BEVATAS vs BEVETEX: Delhi High Court Reverses Permanent Injunction in Landmark Pharmaceutical Trademark Case

Intas Pharmaceuticals Wins Against Sun Pharma: Delhi High Court on Deceptive Similarity of Drug Brand Names

How Delhi High Court Settled the Test for Trademark Infringement in Pharmaceutical Sector: BEVATAS vs BEVETEX Analysis

Section 29(2)(b) Trade Marks Act: Delhi High Court Clarifies Evidentiary Standard for Likelihood of Confusion in Drug Trademark Cases

Post-Trial Trademark Infringement Standard in Pharmaceutical Cases: Delhi High Court 2026 Judgment Explained

Can BEV or BEVA Be Trademarked Exclusively in Anti-Cancer Drugs? Delhi High Court Says No

Public Interest in Pharmaceutical Trademark Suits: Delhi High Court Exposes Vexatious Litigation Tactics


SEO Tags

BEVATAS BEVETEX trademark case, Intas Pharmaceuticals Sun Pharma trademark dispute, Delhi High Court pharmaceutical trademark 2026, Section 29 Trade Marks Act 1999, likelihood of confusion pharmaceutical drugs, deceptive similarity trademark India, Cadila Healthcare Cadila Pharmaceuticals trademark principles, Bevacizumab trademark publici juris, oncology drug trademark infringement, permanent injunction pharmaceutical trademark India, post-trial trademark evidence standard, Schedule H drug trademark confusion, RFA OS COMM 10 2026, 2026 DHC 4879 DB, pharmaceutical trademark India legal analysis, trademark infringement evidence burden of proof India, BEV BEVA trademark common to trade pharmaceutical, Intas Pharmaceuticals trademark victory, Sun Pharma trademark defeat Delhi High Court, anti-cancer drug trademark dispute India, Justice Manmeet Pritam Singh Arora trademark judgment, Justice V Kameswar Rao trademark judgment, Trade Marks Act 1999 Section 29 2 b analysis, passing off vexatious plaint India, pharmaceutical trademark public interest litigation, AdvocateAjayAmitabhSuman, IPAdjutor


Headnote

Intas Pharmaceuticals Limited v. Sun Pharma Laboratories Limited — 2026:DHC:4879-DB — Delhi High Court Division Bench — RFA(OS)(COMM) 10/2026 — Decided May 29, 2026

Trade Marks Act, 1999 — Section 29(2)(b), Section 29(2)(c), Section 29(3), Section 29(4), Section 2(1)(h) — Pharmaceutical Trademark Infringement — Post-Trial Standard — Likelihood of Confusion — Evidentiary Burden — Deceptive Similarity — Publici Juris Prefix.

Held: In a trademark infringement suit under Section 29(2)(b) of the Trade Marks Act, 1999 involving similar but not identical marks and similar but not identical pharmaceutical goods, the court cannot at the post-trial stage grant a permanent injunction based solely on its own visual and phonetic comparison of the marks. An evidence-based assessment of likelihood of confusion among the relevant class of public is mandatory. The statutory presumption of likelihood of confusion under Section 29(3) is available only when both marks and goods are identical under Section 29(2)(c); it cannot be applied to Section 29(2)(b) situations. Two pharmaceutical drugs are not similar goods merely because they fall in Nice Classification Class 5 if they contain different molecules, treat different cancers, are prescribed at different stages of disease, are not interchangeable, and are not perceived as substitutes by Oncologists, chemists, or patients. The prefix BEV/BEVA, being derived from the International Non-Proprietary Name Bevacizumab and used by multiple manufacturers, is publici juris in the pharmaceutical trade; emphasis must be placed on the distinctive uncommon parts of rival marks — here, the suffixes TAS and ETEX — which are phonetically and visually distinct. Sun Pharma's witness PW-1, a sales representative with no direct knowledge of the relevant class of public (chemists, Oncologists, trained nurses), was not a competent witness to prove likelihood of confusion. The plaint was vexatiously framed to include causes of action for passing off and misappropriation of goodwill that Sun Pharma knew to be untenable prior to filing the suit, constituting an abuse of process. Permanent injunction set aside; suit dismissed with costs. (Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73; Kaviraj Pandit Durga Dutt Sharma v. Navaratna Pharmaceutical Laboratories, 1964 SCC OnLine SC 14; Gufic Ltd. v. Clinique Laboratories, LLC & Anr., 2010 (43) PTC 788; Astrazeneca UK Limited & Anr v. Orchid Chemicals & Pharmaceuticals Ltd., ILR (2007) I Delhi 874 — Relied Upon.)

Blog Archive

Featured Post

WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING

WHETHER THE REGISTRAR OF TRADEMARK IS REQUIRED TO BE SUMMONED IN A CIVIL SUIT TRIAL PROCEEDING IN ORDER TO PROVE THE TRADEMARK  REGISTRA...

My Blog List

IPR UPDATE BY ADVOCATE AJAY AMITABH SUMAN

IPR UPDATE BY ADVOCATE AJAY AMITABH SUMAN

Search This Blog